Neurocrine Biosciences, Inc. (NBIX) Cash Flow Statement
Neurocrine Biosciences, Inc. (NBIX) generated $898.1M of operating cash flow over the twelve months to 2026-06-30, spent $27.7M on capital expenditure and had free cash flow of $870.4M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
NBIXNeurocrine Biosciences, Inc.Follow NBIX — free
—
Price chart with a free account
- Market cap
- 14.5B
- P/E TTM
- 20.9
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 2 Nov, in 9 days
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -0.00 | -0.04 | -0.03 | -0.04 | -0.11 | -0.09 | 0.10 | 0.15 | 0.23 | 0.26 | 0.34 | 0.39 | 0.60 | 0.78 | 0.90 | |
| Capital expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.01 | 0.01 | 0.02 | 0.02 | 0.03 | 0.04 | 0.03 | -0.03 | |
| Free cash flow | -0.00 | -0.04 | -0.03 | -0.04 | -0.11 | -0.10 | 0.08 | 0.13 | 0.22 | 0.23 | 0.32 | 0.36 | 0.56 | 0.75 | 0.87 | |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | 0.00 | 0.30 | 0.17 | — | |
| Stock-based compensation | 0.00 | 0.01 | 0.01 | 0.03 | 0.03 | 0.04 | 0.06 | 0.08 | 0.10 | 0.13 | 0.17 | 0.19 | 0.20 | 0.22 | — |
USD billions · SEC XBRL
Neurocrine Biosciences, Inc. — questions
- What is Neurocrine Biosciences, Inc.'s operating cash flow?
- $898.1M over the twelve months to 2026-06-30.
- How much does Neurocrine Biosciences, Inc. spend on capital expenditure?
- $27.7M over the twelve months to 2026-06-30.
- What is Neurocrine Biosciences, Inc.'s free cash flow?
- $870.4M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Neurocrine Biosciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.